Phaseline

Targets › CYP17A1

CYP17A1 (Steroid 17-alpha-hydroxylase/17,20 lyase): drug programs, companies and trials

9 programs from 8 companies in 49 trials: 35 Phase 2, 7 Phase 3, 5 Phase 1, 2 Phase 4; Oncology; next expected readout Nov 2026.

A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis. Catalyzes 17-alpha hydroxylation of C21 steroids, which is common for both pathways. (UniProt, P05093)

Open in Phaseline: the race on CYP17A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaabiraterone acetate
Cytochrome P450 17A1 inhibitor
CYP17A1Phase 3Metastatic Castration-resistant Prostate CancerFeb 2027
Johnson & Johnson (Janssen)Abiraterone acetate
Cytochrome P450 17A1 inhibitor
CYP17A1Phase 3Prostatic Neoplasms; Prostate Cancer; Castration-Resistant Prostatic Cancer; Metastatic Prostate Cancer …Nov 2027
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairAbiraterone
Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist; Steroid 5-alpha-reductase inhibitor
CYP17A1, AR, SRD5A1, SRD5A2, SRD5A3Phase 2Prostate Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Castration Levels of Testosterone; Advanced Prostate Adenocarcinoma …Nov 2026
University of Maryland, Baltimoregaleterone
Androgen Receptor antagonist; Cytochrome P450 17A1 inhibitor
AR, CYP17A1Phase 2Advanced Pancreatic CancerDec 2026
Weill Medical College of Cornell UniversityKetoconazole
Cytochrome P450 51 inhibitor
CYP17A1Phase 2Prostate CancerJun 2027
Sun Pharmaceutical IndustriesAbiraterone acetate
Cytochrome P450 17A1 inhibitor
CYP17A1Phase 2Metastatic CancerDec 2027
AstellasASP5541
CYP17A1 inhibitor (17α-hydroxylase/17,20-lyase inhibitor); intramuscular depot formulation
CYP17A1Phase 2Prostate CancerOct 2028
St Vincent's Hospital, SydneySeviteronel
Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist
CYP17A1, ARPhase 1Triple Negative Breast CancerDec 2027
AstellasPRL-02 injection
Abiraterone decanoate - CYP17A1 inhibitor for testosterone reduction
CYP17A1Phase 1Prostate CancerMay 2029

Conditions

Prostate Cancer (14) Metastatic Prostate Cancer (3) Castration Levels of Testosterone (3) Metastatic Castration-resistant Prostate Cancer (3) Prostatic Neoplasms (2) Metastatic Prostate Carcinoma (2) Prostate Adenocarcinoma (2) Prostatic Neoplasms, Castration-Resistant (2) Castration-Resistant Prostatic Cancer (1) Neoadjuvant Therapy (1) Metastatic Prostate Adenocarcinoma (1) Prostate Cancer Metastatic Castration-Resistant (1)

Modalities

small molecule (9)

Companies

Astellas (2) Johnson & Johnson (Janssen) (1) AstraZeneca (1) Weill Medical College of Cornell University (1) St Vincent's Hospital, Sydney (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) Sun Pharmaceutical Industries (1) University of Maryland, Baltimore (1)

Related targets

AR (3) SRD5A1 (1) SRD5A2 (1) SRD5A3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.